Breaking News

Moderna Cuts R&D Spending, Focuses on Oncology

Aims to reduce annual research and development expenses by approximately $1.1 billion starting in 2027.

Author Image

By: Charlie Sternberg

Associate Editor

Moderna has announced plans to take a “more selective and paced” approach to its research and development investment. Through portfolio prioritization and cost efficiencies, the company aims to reduce annual research and development expenses by approximately $1.1 billion starting in 2027.   The company aims to complete most of its respiratory investments by 2026. Meanwhile, it’s increasing research and development investments in oncology, and pacing its investments in latent and other vaccines...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters